Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00045435 |
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well donor peripheral stem cell transplant works in treating older patients with acute myeloid leukemia.
Condition | Intervention | Phase |
---|---|---|
Leukemia |
Drug: cyclosporine Drug: fludarabine phosphate Drug: mycophenolate mofetil Drug: therapeutic allogeneic lymphocytes Procedure: peripheral blood stem cell transplantation Procedure: radiation therapy |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantaion From HLA Matched Related Donors for Treatment of Older Patients With De Novo or Secondary Acute Myeloid Leukemia in First Complete Remission |
Estimated Enrollment: | 40 |
Study Start Date: | April 2002 |
Estimated Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study.
Patients receive fludarabine IV on days -4 to -2. Patients undergo total body irradiation followed by allogeneic peripheral blood stem cell infusion on day 0. Patients receive oral cyclosporine twice daily on days -3 to 56 followed by a taper on days 57-77 and oral mycophenolate mofetil twice daily on days 0-27.
After completion of study therapy, patients are followed at approximately 1, 4, 10, and 16 months and then annually thereafter.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 4 years.
Ages Eligible for Study: | 55 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Availability of a related donor who is genotypically or phenotypically identical
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Pulmonary
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
United States, Oregon | |
Oregon Health and Science University Cancer Institute | |
Portland, Oregon, United States, 97239-3098 | |
United States, Utah | |
Huntsman Cancer Institute at University of Utah | |
Salt Lake City, Utah, United States, 84112 | |
United States, Washington | |
Fred Hutchinson Cancer Research Center | |
Seattle, Washington, United States, 98109-1024 | |
Seattle Cancer Care Alliance | |
Seattle, Washington, United States, 98109-1023 | |
Veterans Affairs Medical Center - Seattle | |
Seattle, Washington, United States, 98108 |
Study Chair: | Brenda Sandmaier, MD | Fred Hutchinson Cancer Research Center |
Responsible Party: | Fred Hutchinson Cancer Research Center ( Brenda Sandmaier ) |
Study ID Numbers: | CDR0000256466, FHCRC-1654.00 |
Study First Received: | September 6, 2002 |
Last Updated: | October 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00045435 |
Health Authority: | United States: Federal Government |
adult acute erythroid leukemia (M6) adult acute megakaryoblastic leukemia (M7) adult acute minimally differentiated myeloid leukemia (M0) adult acute myeloblastic leukemia with maturation (M2) adult acute myeloblastic leukemia without maturation (M1) adult acute myelomonocytic leukemia (M4) secondary acute myeloid leukemia |
adult acute myeloid leukemia in remission adult acute monocytic leukemia (M5b) adult acute monoblastic leukemia (M5a) adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) |
Leukemia, Monocytic, Acute Cyclosporine Clotrimazole Miconazole Tioconazole Acute myelogenous leukemia Acute myelomonocytic leukemia Fludarabine monophosphate Leukemia, Myeloid Leukemia, Myeloid, Acute Di Guglielmo's syndrome Cyclosporins |
Leukemia, Myelomonocytic, Acute Leukemia Leukemia, Erythroblastic, Acute Mycophenolate mofetil Neoplasm Metastasis Acute erythroblastic leukemia Fludarabine Acute myeloid leukemia, adult Congenital Abnormalities Acute monoblastic leukemia Acute myelocytic leukemia |
Antimetabolites Anti-Infective Agents Antimetabolites, Antineoplastic Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs |
Enzyme Inhibitors Immunosuppressive Agents Pharmacologic Actions Neoplasms Antifungal Agents Therapeutic Uses Antirheumatic Agents Dermatologic Agents |